Evofem announces that Solosec treatment patent is included in FDA Orange Book
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Patent Announcement: Evofem Biosciences has received a new U.S. patent for SOLOSEC 2 g oral granules, which is now included in the FDA's Orange Book.
Importance of Listing: The inclusion in the Orange Book is seen as a significant step in enhancing Evofem's patent portfolio and market position.
Extended Exclusivity: The patent extends SOLOSEC's intellectual property and market exclusivity until December 2041, benefiting prescribers, patients, and investors.
Product Significance: SOLOSEC is noted as the first and only single-dose oral treatment FDA-approved for both bacterial vaginosis (BV) and trichomoniasis in the U.S.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
